Global Liquid Biopsy For Cancer Diagnostics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Liquid Biopsy For Cancer Diagnostics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Liquid biopsy for cancer diagnostics refers to a non-invasive medical test that analyzes blood or other body fluids to detect and analyze genetic alterations, proteins, or other molecules associated with cancer. Unlike traditional biopsies, which involve the surgical removal of a tissue sample, liquid biopsies provide a less invasive and more accessible method for detecting and monitoring cancer.
Global Liquid Biopsy For Cancer Diagnostics market is projected to reach US$ 7887.5 million in 2033, increasing from US$ 3603.7 million in 2022, with the CAGR of 12.4% during the period of 2023 to 2033. Demand from Hospital and Diagnostic Center are the major drivers for the industry.
Researchers and developers continue to explore and expand the clinical utility of liquid biopsy. This includes investigating its application in various cancer types, different stages of cancer, and for monitoring treatment response and minimal residual disease.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Liquid Biopsy For Cancer Diagnostics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
F. Hoffman La Roche Ltd.
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Illumina Inc.
The Menarini Group
Bio-Rad Laboratories Inc.
QIAGEN Inc.
Exact Sciences Corporation
Bio-Techne Corporation
ArcherDX Inc.
Neogenomics Laboratories Inc.
Guardant Health Inc.
Myriad Genetics Inc.
Foundation Medicine Inc.
Amoy Diagnostics Co. Ltd.
Biocartis Group NV
Segment by Type
Blood Test
Urine Test
Saliva Test
Hospital
Diagnostic Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Liquid Biopsy For Cancer Diagnostics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Liquid Biopsy For Cancer Diagnostics introduction, etc. Liquid Biopsy For Cancer Diagnostics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Liquid Biopsy For Cancer Diagnostics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Global Liquid Biopsy For Cancer Diagnostics market is projected to reach US$ 7887.5 million in 2033, increasing from US$ 3603.7 million in 2022, with the CAGR of 12.4% during the period of 2023 to 2033. Demand from Hospital and Diagnostic Center are the major drivers for the industry.
Researchers and developers continue to explore and expand the clinical utility of liquid biopsy. This includes investigating its application in various cancer types, different stages of cancer, and for monitoring treatment response and minimal residual disease.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Liquid Biopsy For Cancer Diagnostics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
F. Hoffman La Roche Ltd.
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Illumina Inc.
The Menarini Group
Bio-Rad Laboratories Inc.
QIAGEN Inc.
Exact Sciences Corporation
Bio-Techne Corporation
ArcherDX Inc.
Neogenomics Laboratories Inc.
Guardant Health Inc.
Myriad Genetics Inc.
Foundation Medicine Inc.
Amoy Diagnostics Co. Ltd.
Biocartis Group NV
Segment by Type
Blood Test
Urine Test
Saliva Test
Segment by Application
Hospital
Diagnostic Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Liquid Biopsy For Cancer Diagnostics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Liquid Biopsy For Cancer Diagnostics introduction, etc. Liquid Biopsy For Cancer Diagnostics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Liquid Biopsy For Cancer Diagnostics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices